These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 35271729)
21. Antiviral Efficacy of Molnupiravir for COVID-19 Treatment. Bai Y; Shen M; Zhang L Viruses; 2022 Apr; 14(4):. PubMed ID: 35458493 [TBL] [Abstract][Full Text] [Related]
22. Transporter modulation of molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-brain barrier in a rat. Chang CH; Peng WY; Lee WH; Yang L; Lin TY; Yang MH; Tsai TH Commun Med (Lond); 2023 Oct; 3(1):150. PubMed ID: 37857815 [TBL] [Abstract][Full Text] [Related]
23. Molnupiravir: an antiviral drug against COVID-19. Dave B; Shah KC; Chorawala MR; Shah N; Patel P; Patel S; Shah P Arch Virol; 2023 Sep; 168(10):252. PubMed ID: 37710056 [TBL] [Abstract][Full Text] [Related]
24. Molnupiravir: A new candidate for COVID-19 treatment. Pourkarim F; Pourtaghi-Anvarian S; Rezaee H Pharmacol Res Perspect; 2022 Feb; 10(1):e00909. PubMed ID: 34968008 [TBL] [Abstract][Full Text] [Related]
25. What impact can molnupiravir have on the treatment of SARS-CoV-2 infection? Kayali F; Leung MST; Wong W; Morgan KP; Harky A Expert Opin Pharmacother; 2022 Jun; 23(8):865-868. PubMed ID: 35341442 [No Abstract] [Full Text] [Related]
26. Molnupiravir: Mechanism of action, clinical, and translational science. Maas BM; Strizki J; Miller RR; Kumar S; Brown M; Johnson MG; Cheng M; De Anda C; Rizk ML; Stone JA Clin Transl Sci; 2024 Feb; 17(2):e13732. PubMed ID: 38593352 [TBL] [Abstract][Full Text] [Related]
27. Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19. Arribas JR; Bhagani S; Lobo SM; Khaertynova I; Mateu L; Fishchuk R; Park WY; Hussein K; Kim SW; Ghosn J; Brown ML; Zhang Y; Gao W; Assaid C; Grobler JA; Strizki J; Vesnesky M; Paschke A; Butterton JR; De Anda C NEJM Evid; 2022 Feb; 1(2):EVIDoa2100044. PubMed ID: 38319178 [TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of molnupiravir in SARS-CoV-2-infected patients: A real-life experience. De Vito A; Colpani A; Bitti A; Zauli B; Meloni MC; Fois M; Denti L; Bacciu S; Marcia C; Maida I; Babudieri S; Madeddu G J Med Virol; 2022 Nov; 94(11):5582-5588. PubMed ID: 35855627 [TBL] [Abstract][Full Text] [Related]
29. Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic. Khiali S; Khani E; B Rouy S; Entezari-Maleki T Future Microbiol; 2022 Mar; 17(5):377-391. PubMed ID: 35199608 [TBL] [Abstract][Full Text] [Related]
30. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. Jayk Bernal A; Gomes da Silva MM; Musungaie DB; Kovalchuk E; Gonzalez A; Delos Reyes V; Martín-Quirós A; Caraco Y; Williams-Diaz A; Brown ML; Du J; Pedley A; Assaid C; Strizki J; Grobler JA; Shamsuddin HH; Tipping R; Wan H; Paschke A; Butterton JR; Johnson MG; De Anda C; N Engl J Med; 2022 Feb; 386(6):509-520. PubMed ID: 34914868 [TBL] [Abstract][Full Text] [Related]
34. Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro. Jonsdottir HR; Siegrist D; Julien T; Padey B; Bouveret M; Terrier O; Pizzorno A; Huang S; Samby K; Wells TNC; Boda B; Rosa-Calatrava M; Engler OB; Constant S Biomed Pharmacother; 2022 Jun; 150():113058. PubMed ID: 35658229 [TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 RdRp uses NDPs as a substrate and is able to incorporate NHC into RNA from diphosphate form molnupiravir. Wang M; Wu C; Liu N; Zhang F; Dong H; Wang S; Chen M; Jiang X; Zhang K; Gu L Int J Biol Macromol; 2023 Jan; 226():946-955. PubMed ID: 36528144 [TBL] [Abstract][Full Text] [Related]
37. Development and validation of assays for the quantification of β-D-N Parsons TL; Kryszak LA; Marzinke MA J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Oct; 1182():122921. PubMed ID: 34555541 [TBL] [Abstract][Full Text] [Related]
38. β-d-N Konishi K; Kusakabe S; Kawaguchi N; Shishido T; Ito N; Harada M; Inoue S; Maeda K; Hall WW; Orba Y; Sawa H; Sasaki M; Sato A Antiviral Res; 2024 Sep; 229():105977. PubMed ID: 39089332 [TBL] [Abstract][Full Text] [Related]
40. A validated LC-MS/MS method for determination of antiviral prodrug molnupiravir in human plasma and its application for a pharmacokinetic modeling study in healthy Egyptian volunteers. Gouda AS; Marzouk HM; Rezk MR; Salem AM; Morsi MI; Nouman EG; Abdallah YM; Hassan AY; Abdel-Megied AM J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Aug; 1206():123363. PubMed ID: 35810537 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]